Johns Hopkins HIV Guide
Etravirine (ETR)
INDICATIONS
FDA
FDA
- In combination with other ARV agents for treating HIV-1 infection in treatment-experienced pts with PIs-, NRTIs-, and NNRTI-resistant variants.
- Treatment-experienced HIV-infected pediatric patients (6 -18 years of age and weighing at least 16 kg).
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Potential for use in first-line therapy for pts infected with NNRTI-resistant virus (untested)
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: July 16, 2023
Citation
Auwaerter, Paul G, et al. "Etravirine (ETR)." Johns Hopkins HIV Guide, 2023. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545070/all/Etravirine__ETR_.
Auwaerter PG, Pham PA, Hsu AJ. Etravirine (ETR). Johns Hopkins HIV Guide. 2023. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545070/all/Etravirine__ETR_. Accessed December 1, 2023.
Auwaerter, P. G., Pham, P. A., & Hsu, A. J. (2023). Etravirine (ETR). In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545070/all/Etravirine__ETR_
Auwaerter PG, Pham PA, Hsu AJ. Etravirine (ETR) [Internet]. In: Johns Hopkins HIV Guide. ; 2023. [cited 2023 December 01]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545070/all/Etravirine__ETR_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Etravirine (ETR)
ID - 545070
A1 - Auwaerter,Paul,M.D.
AU - Pham,Paul,Pharm.D. BCPS
AU - Hsu,Alice,Pharm.D
Y1 - 2023/07/16/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545070/all/Etravirine__ETR_
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
